Lyon Joseph Douglas's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 4, 2025
- Accession no.
- 0001193125-25-196317
- Filed
- Sep 4, 2025
- Trade date
- Sep 2-3, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $351.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyon Joseph DouglasCIK 0001817838 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Common Stock | MOption exerciseAcquired | +5,000 | $13.56 | +$67,800 | 15,066 | Direct | |
| Sep 2, 2025 | Common Stock | SSaleDisposed | −4,895 | $70.24F3 | −$343,824.8 | 10,171 | Direct | |
| Sep 2, 2025 | Common Stock | SSaleDisposed | −105 | $70.76F4 | −$7,429.8 | 10,066 | Direct | |
| Sep 2, 2025 | Common Stock | AGrant or awardAcquired | +200 | $71.38F6 | +$14,276 | 10,266 | Direct | |
| Sep 2, 2025 | Common Stock | AGrant or awardAcquired | +200 | $0.00 | $0 | 10,466 | Direct | |
| Sep 3, 2025 | Common Stock | FTax withholdingDisposed | −189 | $71.38F9 | −$13,490.82 | 10,277 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 26,571 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.74 to $70.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F6
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F9
The closing price on September 2, 2025 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Accounting & Technology Officer